JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kikuchi, K.
Right arrow Articles by Chen, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kikuchi, K.
Right arrow Articles by Chen, K. K.
Journal of Pharmacology And Experimental Therapeutics, Vol. 146, Issue 3, 365-368, 1964
Copyright © 1964 by American Society for Pharmacology and Experimental Therapeutics

PHARMACOLOGY OF RHODEXIN A

Kenzo Kikuchi 1 and K. K. Chen 1

1 Department of Pharmacology, Indiana University School of Medicine, Indianapotis, Indiana

The cardiotonic action of rhodexin A, sarmentogenin rhamnoside, has been confirmed both qualitatively and quantitatively. The geometric mean dose in etherized cats is 0.1059 ± 0.0028 mg/kg.

The degree of intestinal absorption is estimated by measuring the median emetic dose in groups of etherized cats following intrajejunal and intravenous injections because vomiting response precedes electrocardiographic changes. About 20% of rhodexin A and 75% Of digitoxin are absorbed from the jejunum.

By direct perfusion of the sinus node of the dog's heart, the chronotropic effect of rhodexin A is found comparable to that of acetylstrophanthidin, but longer and more intense.

DCI, procaine amide, visnadin, and agr-methyl-beta-hydroxy-beta(2,5-diethoxyphenyl)-N-isopropyl-ethylamine are tested for their antiarrhythmic action against rhodexin A-induced ventricular tachycardia in cats. Visnadin is inactive, while the other three compounds are capable of restoring sinus rhythm in various doses. There is a suggestion that the last product is slightly more potent than the other two.

Accepted on August 12, 1964






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1964 by the American Society for Pharmacology and Experimental Therapeutics.